Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationEBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - Other
Ratios

Theravance Biopharma (TBPH) Non-Current Receivables (2017 - 2020)

Theravance Biopharma (TBPH) has disclosed Non-Current Receivables for 4 consecutive years, with $4.0 million as the latest value for Q2 2020.

  • On a quarterly basis, Non-Current Receivables rose 7.88% to $4.0 million in Q2 2020 year-over-year; TTM through Jun 2020 was $4.0 million, a 7.88% increase, with the full-year FY2019 number at $3.7 million, changed N/A from a year prior.
  • Non-Current Receivables was $4.0 million for Q2 2020 at Theravance Biopharma, roughly flat from $4.0 million in the prior quarter.
  • In the past five years, Non-Current Receivables ranged from a high of $8.2 million in Q4 2017 to a low of $3.1 million in Q3 2018.
  • A 4-year average of $4.5 million and a median of $3.7 million in 2019 define the central range for Non-Current Receivables.
  • Peak YoY movement for Non-Current Receivables: plummeted 61.2% in 2018, then rose 17.56% in 2019.
  • Theravance Biopharma's Non-Current Receivables stood at $8.2 million in 2017, then crashed by 61.78% to $3.1 million in 2018, then increased by 17.6% to $3.7 million in 2019, then rose by 8.26% to $4.0 million in 2020.
  • Per Business Quant, the three most recent readings for TBPH's Non-Current Receivables are $4.0 million (Q2 2020), $4.0 million (Q1 2020), and $3.7 million (Q4 2019).